Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.
PisoniRRuggenentiPRemuzziG. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf2001; 24: 491–501.
2.
MoakeJL. Thrombotic microangiopathies. N Engl J Med2002; 347: 589–600.
3.
Blake-HaskinsJALechleiderRJKreitmanRJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res2011; 17: 5858–5866.
4.
KavanaghDGoodshipTHJRichardsA. Atypical haemolytic uraemic syndrome. Br Med Bull2006; 77–78: 5–22.
5.
GeorgeJNNesterCM. Syndromes of thrombotic microangiopathy. N Engl J Med2014; 371: 654–666.
6.
IzzedineHPerazellaMA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis2015; 66: 857–868.
7.
LechnerKObermeierHL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore)2012; 91: 195–205.
8.
LiuKMittelmanASproulEE. Renal toxicity in man treated with mitomycin C. Cancer1971; 28: 1314–1320.
9.
El-GhazalRPodoltsevNMarksP. Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer2011; 10(2): 142–145.
10.
WuDCLiuJMChenYM. Mitomycin-C induced hemolytic uremic syndrome: A case report and literature review. Jpn J Clin Oncol1997; 27: 115–118.
11.
LesesneJBRothschildNEricksonB. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol1989; 7: 781–789.
12.
OnitiloAAEngelJMClouseLH. Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. J Vasc Interv Radiol2009; 20: 275–276.
13.
CattellV. Mitomycin-induced hemolytic uremic kidney: an experimental model in the rat. Am J Pathol1985; 121: 88–95.
14.
CantrellJEPhillipsTMScheinPS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol1985; 3: 723–734.
15.
ZimmermanSESmithFPPhillipsTM. Gastric carcinoma and thrombotic thrombocytopenic purpura: associated with plasma immune complex concentrations. Br Med J (Clin Res Ed)1982; 284: 1432–1434.
16.
SheldonRSlaughterD. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer1986; 58: 1428–1436.
17.
VerweyJBovenEvan der MeulenJ. Recovery from mitomycin C-induced hemolytic uremic syndrome: a case report. Cancer1984; 54: 2878–2881.
18.
WenMCChenCHHoWL. Mitomycin C-induced renal insufficiency: a case report. Kaohsiung J Med Sci2003; 19: 317–321.
19.
D’EliaJAAslaniMSchermerS. Hemolytic-uremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review. Ren Fail1987; 10: 107–113.
20.
PriceTMMurgoAJKeveneyJJ. Renal failure and hemolytic anemia associated with mitomycin C: a case report. Cancer1985; 55: 51–56.
21.
HongMJLeeHGHurM. Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment. Korean J Hematol2011; 46: 45–48.
22.
CasperESGreenMRKelsenDP. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs1994; 12: 29–34.
23.
MullerSSchuttPBojkoP. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol2005; 84: 110–114.
GlezermanIKrisMGMillerV. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol2009; 71: 130–139.
28.
De SmetDJochmansKNeynsB. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol2008; 87: 495–496.
29.
ThomasJGSethiSNorbySM. Chronic thrombotic microangiopathy secondary to chemotherapy for urothelial carcinoma in a patient with a history of Wegener granulomatosis. Am J Kidney Dis2011; 57: 799–802.
30.
WalterRBJoergerMPestalozziBC. Gemcitabine-associated emolytic-uremic syndrome. Am J Kidney Dis2002; 40: E16–E16.
31.
LewinSNMutchDGWhitcombBP. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol2005; 97: 228–233.
32.
GoreEMJonesBSMarquesMB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?J Clin Apher2009; 24: 209–214.
33.
BharthuarAEgloffLBeckerJ. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother Pharmacol2009; 64: 177–181.
34.
GourleyBLMesaHGuptaP. Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemother Pharmacol2010; 65: 1001–1004.
35.
StarckMWendtnerCM. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol. Epub ahead of print 4 December 2013. DOI: 10.1111/bjh.12686.
36.
NishijimaYHirataHHimenoA. Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. Intern Med2013; 52: 1111–1114.
37.
PalmisanoJAgraharkarMKaplanAA. Successful treatment of cisplatin-induced hemolytic uremic syndrome with therapeutic plasma exchange. Am J Kidney Dis1998; 32: 314–317.
38.
van der HeijdenMAcklandSPDeveridgeS. Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy. Acta Oncol1998; 37: 107–109.
39.
GardnerGMeslerDGitelmanHJ. Hemolytic uremic syndrome following cisplatin, bleomyycin, and vincristine chemotherapy: a report of a case and a review of the literature. Ren Fail1989; 11: 133–137.
40.
GradisharWJVokesEENiK. Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer: a case report. Cancer1990; 66: 1914–1918.
41.
MathurRKumarSAparicioS. Haemolytic uraemic syndrome following chemotherapy for an unusual germ-cell tumor. Nephrol Dial Transplant1999; 14: 1786–1788.
42.
NiuJMimsMP. Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. J Clin Oncol2012; 30: e312–e314.
43.
LucchesiACarloniSCanginiD. Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report and results from a cytoflourimetric assay of platelet fibrinogen receptor. J Clin Oncol2013; 31: 2061–2062.
44.
BarettaZFalciCPivaE. Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report. Clin Colorectal Cancer2013; 12: 294–296.
45.
DahabrehITsoutsosGTselgias. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol2006; 6: 5–5.
46.
KwaMBaumgartnerRShavitL. Is renal thrombotic microangiopathy an emerging problem in the treatment of ovarian cancer recurrences?Oncologist2012; 17: 1534–1540.
LeachJWPhamTDiamandidisD. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report. AM J Hematol. 61: 268–270.
49.
SakaiCTakagiTWakatsukiS. Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case. Intern Med1995; 34: 593–596.
50.
SiauKVarugheseM. Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol2010; 27: 1057–1059.
51.
IamsWBeckermannKENeffAT. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Med Oncol2013; 30: 568–568.
52.
RegraguiSAmelalSAstatiS. Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case Rep Hematol2012; 2012: 806476–806476.
53.
DalyASXenocostasALiptonJH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant2002; 30: 709–715.
54.
IacopinoPPucciGArceseW. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Bone Marrow Transplant1999; 24: 47–51.
55.
CutlerCLoganBNakamuraR. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogenic HCT. Blood2014; 124: 1372–1377.
56.
LabradorJLópez-CorralLLópez-GodinoO. Risk factors for thrombotic microangiopathy in allogenic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus. Bone Marrow Transplant2014; 49: 684–690.
57.
ShayaniSPalmerJStillerT. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic stem cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant2013; 19: 298–304.
58.
OhnoEOhtsukaEIwashitaT. Hemolytic uremic syndrome following autologous peripheral blood stem cell transplantation in a patient with malignant lymphoma. Bone Marrow Transplant1997; 19: 1045–1047.
59.
van der LelieHBaarsJWRodenhuisS. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer1995; 76: 2338–2342.
60.
VantelonJMMunckJNBourhisJH. Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. Bone Marrow Transplant2001; 27: 531–536.
61.
MageeCCAbrahamKFarrellJ. Renal thrombotic microangiopathy associated with interferon-α treatment of chronic myeloid leukemia. Am J Kidney Dis2000; 36: E5–E5.
Ravandi-KashaniFCortesJTalpazM. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?Cancer1999; 85: 2583–2588.
66.
HondaKAndoAEndoM. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia. Am J Kidney Dis1997; 30: 123–130.
67.
OhashiNYonemuraKSugiuraT. Withdrawal of interferon-α results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-α. Am J Kidney Dis2003; 41: E10–E10.
68.
Vacher-CoponatHOprisADanielL. Thrombotic microangiopathy in a patient with chronic myelocytic leukaemia treated with α-interferon. Nephrol Dial Transplant1999; 14: 2469–2471.
69.
PolitouMTsaftaridesPVassiliadesJ. Thrombotic microangiopathy in a patient with Sezary syndrome treated with interferon-α. Nephrol Dial Transplant2004; 19: 733–735.
70.
StrattaPCanaveseCDoglianiM. Hemolytic-uremic syndrome during recombinant alpha-interferon treatment for hairy cell leukemia. Ren Fail1993; 15: 559–561.
71.
AlexandrescuDTMaddukuriPWiernikP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma. J Immunother2005; 28: 144–147.
72.
SalmenniemiURemesK. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep2012; 4: e13–e13.
73.
MooreHRomerilK. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J2011; 41: 348–350.
MoritaRHashinoSShiraiS. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol2008; 88: 248–250.
HobeikaLSelfSEVelezJCQ. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol2014; 15: 156–156.
78.
ShorttJOhDHOpatSS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med2013; 368: 90–92.
79.
MazepaMARavalJSMollS. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol2014; 164: 900–902.
80.
IzzedineHEscudierBLhommeC. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore)2014; 93: 333–339.
81.
EreminaVJeffersonJAKowalewskaJ. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med2008; 358: 1129–1136.
82.
RonconeDSatoskarANadasdyT. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol2007; 3: 287–293.
83.
StokesMBErazoMCD’AgatiVD. Glomerular disease related to anti-VEGF therapy. Kidney Int2008; 74: 1487–1491.
84.
FrangiéCLefaucheurCMedioniJ. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol2007; 8: 177–178.
85.
KorkmazSKılıçkapSTerziH. Sunitinib-induced microangiopathic hemolytic anemia: a case report. Erciyes Med J2014; 36: 88–90.
86.
CosteroOPicazoMLZamoraP. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microagiopathy. Nephrol Dial Transplant2010; 25: 1001–1003.
87.
KapiteijnEBrandAKroepJ. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol2007; 18: 1745–1747.
88.
El DikaIMukherjiDTemrazS. Sunitinib induced thrombotic thrombocytopenic purpura in addition to severe hypothyroidism: a case report and review of the literature. Case Rep Med2014; 2014: 958414–958414.
89.
LeveySABajwaRSPickenMM. Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation. NDT Plus2008; 1: 154–156.
90.
BolléeGPateyNCazajousG. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant2009; 24: 682–685.
91.
TalebiTNStefanovicAMerchanJ. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. Am J Ther2012; 19: e143–e145.
92.
FeldmanDRBaumMSGinsbergMS. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol2009; 27: 1432–1439.
93.
IzzedineHSèneDHadouxJ. Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?Ann Oncol2011; 22: 487–490.
94.
IsaacsJDMannaVKRapsonN. Campath-1H in rheumatoid arthritis – an intravenous dose-ranging study. Br J Rheumatol1996; 35: 231–240.
95.
AlAZPhiloctêteAJMGellensME. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?Am J Kidney Dis2005; 45: 762–768.
